MARKET

UMRX

UMRX

Unum Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
-0.080
-7.02%
After Hours: 1.070 +0.01 +0.94% 18:43 01/24 EST
OPEN
1.150
PREV CLOSE
1.140
HIGH
1.180
LOW
1.000
VOLUME
298.01K
TURNOVER
--
52 WEEK HIGH
4.870
52 WEEK LOW
0.4760
MARKET CAP
32.50M
P/E (TTM)
-0.7526
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of UMRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

UMRX News

  • Did Changing Sentiment Drive Unum Therapeutics's (NASDAQ:UMRX) Share Price Down A Painful 77%?
  • Simply Wall St..01/17 18:56
  • Hedge Funds Are Selling Unum Therapeutics Inc. (UMRX)
  • Insider Monkey.12/22/2019 22:09
  • The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win
  • Benzinga.12/12/2019 12:38
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.12/11/2019 12:21

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About UMRX

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.
More

Webull offers Unum Therapeutics Inc (UMRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.